Dietary interventions in metabolic dysfunction-associated steatotic liver disease: current evidence, research priorities, and clinical translation
- 1Department of Environmental Medicine, Poznan University of Medical Sciences, Poznan, Poland
- 2Collegium Medicum of Jan Kochanowski University, Kielce, Poland
- 3Department of Infectious Diseases and Hepatology, Medical University of Silesia, Katowice, Poland
Abstract
Metabolic dysfunction-associated steatotic liver disease (MASLD) is closely linked to excess adiposity, insulin resistance, and adverse dietary patterns. Dietary management is a potentially disease-modifying component of care, but no single standardized “MASLD diet” applies to all patients. This narrative review evaluates energy restriction, Mediterranean-style eating, low-carbohydrate, ketogenic, dietary approaches to stop hypertension (DASH), intermittent fasting, vegetarian, and plant-based approaches, together with practical food-based recommendations. The strongest evidence supports improved dietary quality and, in patients with excess body weight, a sustainable energy deficit that produces clinically meaningful weight loss. Mediterranean-style eating remains the best-supported named pattern, although evidence is stronger for liver fat and cardiometabolic outcomes than for histological or clinical liver outcomes. Management should prioritize minimally processed, predominantly plant-based, fiber-rich foods and unsaturated fats while limiting sugar-sweetened beverages, refined carbohydrates, ultra-processed foods, red and processed meat, and alcohol. Normal-weight MASLD, cirrhosis, and incretin-associated weight loss require individualized goals emphasizing metabolic control, nutritional adequacy, and muscle preservation.
Related
- Omics-based Decoding of Metabolic Dysfunction-associated Fatty Liver Disease: From Pathogenesis to Clinical Translation
- Omics-derived signatures in metabolic dysfunction-associated steatotic liver disease: from molecular characterization to clinical translation.
- Effectiveness of eHealth lifestyle interventions on management of metabolic dysfunction-associated steatotic liver disease: a systematic review and meta-analysis.
- Mobile application-enabled lifestyle interventions for metabolic dysfunction-associated steatotic liver disease: a systematic review and meta-analysis
- Efficacy and safety of GLP-1 receptor agonists in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) : A systematic review and meta-analysis
BibTeX
@article{choreziak2026dietary,
title = {{Dietary interventions in metabolic dysfunction-associated steatotic liver disease: current evidence, research priorities, and clinical translation}},
author = {Anna Choręziak and Piotr Rzymski and Barbara Poniedziałek and Krystyna Dobrowolska and Michał Brzdęk and Jerzy Jaroszewicz and Dorota Zarębska-Michaluk},
journal = {Clinical and Experimental Hepatology},
year = {2026},
month = sep,
doi = {10.5114/ceh.2026.164368},
url = {https://doi.org/10.5114/ceh.2026.164368},
note = {CC BY-NC-SA 4.0},
}
RIS
TY - JOUR
TI - Dietary interventions in metabolic dysfunction-associated steatotic liver disease: current evidence, research priorities, and clinical translation
AU - Anna Choręziak
AU - Piotr Rzymski
AU - Barbara Poniedziałek
AU - Krystyna Dobrowolska
AU - Michał Brzdęk
AU - Jerzy Jaroszewicz
AU - Dorota Zarębska-Michaluk
PY - 2026
DA - 2026/09/08
JO - Clinical and Experimental Hepatology
DO - 10.5114/ceh.2026.164368
UR - https://doi.org/10.5114/ceh.2026.164368
AB - Metabolic dysfunction-associated steatotic liver disease (MASLD) is closely linked to excess adiposity, insulin resistance, and adverse dietary patterns. Dietary management is a potentially disease-modifying component of care, but no single standardized “MASLD diet” applies to all patients. This narrative review evaluates energy restriction, Mediterranean-style eating, low-carbohydrate, ketogenic, dietary approaches to stop hypertension (DASH), intermittent fasting, vegetarian, and plant-based approaches, together with practical food-based recommendations. The strongest evidence supports improved dietary quality and, in patients with excess body weight, a sustainable energy deficit that produces clinically meaningful weight loss. Mediterranean-style eating remains the best-supported named pattern, although evidence is stronger for liver fat and cardiometabolic outcomes than for histological or clinical liver outcomes. Management should prioritize minimally processed, predominantly plant-based, fiber-rich foods and unsaturated fats while limiting sugar-sweetened beverages, refined carbohydrates, ultra-processed foods, red and processed meat, and alcohol. Normal-weight MASLD, cirrhosis, and incretin-associated weight loss require individualized goals emphasizing metabolic control, nutritional adequacy, and muscle preservation.
SN - 2392-1099
SN - 2449-8238
ER -